JP7612591B2 - 抗ｃｌｅｃ２ｄ抗体及びその使用方法 - Google Patents

抗ｃｌｅｃ２ｄ抗体及びその使用方法 Download PDF

Info

Publication number
JP7612591B2
JP7612591B2 JP2021547303A JP2021547303A JP7612591B2 JP 7612591 B2 JP7612591 B2 JP 7612591B2 JP 2021547303 A JP2021547303 A JP 2021547303A JP 2021547303 A JP2021547303 A JP 2021547303A JP 7612591 B2 JP7612591 B2 JP 7612591B2
Authority
JP
Japan
Prior art keywords
seq
clec2d
antibody
antigen
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021547303A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521705A (ja
JP2022521705A5 (https=
JPWO2020167668A5 (https=
Inventor
カビタ アイヤール ロドリゲス，
マロイ ゴーシュ，
スニト マイティ，
ヨゲンドラ マンジュナト バンガロール ムニラジュ，
サティヤバラン ムルゲサン，
サンガミトラ バッタチャルジー，
ヴィヴェク ハラン，
シュブラ プラカシュ チャクラバルティ，
アシュビニ クマール ドゥビー，
アヌラグ ティワリ，
キルタナ マイソール ヴァスデヴァラオ シンデー，
パラヴィ ラヒリ，
サハナ ビマ ラオ，
プラチ
シュルティ スリヴァスタヴァ，
ラオ シュリーシャ ラメシュ，
バラス ラヴィンドラ シェノイ，
ニキタ マルカンダ，
バギャシュリー デッキー，
バイラヴァバラクマール ナタラジャン，
Original Assignee
ズムトール バイオロジクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ズムトール バイオロジクス インコーポレイテッド filed Critical ズムトール バイオロジクス インコーポレイテッド
Publication of JP2022521705A publication Critical patent/JP2022521705A/ja
Publication of JP2022521705A5 publication Critical patent/JP2022521705A5/ja
Publication of JPWO2020167668A5 publication Critical patent/JPWO2020167668A5/ja
Priority to JP2024229509A priority Critical patent/JP2025062598A/ja
Application granted granted Critical
Publication of JP7612591B2 publication Critical patent/JP7612591B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021547303A 2019-02-11 2020-02-10 抗ｃｌｅｃ２ｄ抗体及びその使用方法 Active JP7612591B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024229509A JP2025062598A (ja) 2019-02-11 2024-12-25 抗ｃｌｅｃ２ｄ抗体及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201941005395 2019-02-11
IN201941005395 2019-02-11
PCT/US2020/017518 WO2020167668A1 (en) 2019-02-11 2020-02-10 Anti-clec2d antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024229509A Division JP2025062598A (ja) 2019-02-11 2024-12-25 抗ｃｌｅｃ２ｄ抗体及びその使用方法

Publications (4)

Publication Number Publication Date
JP2022521705A JP2022521705A (ja) 2022-04-12
JP2022521705A5 JP2022521705A5 (https=) 2023-02-20
JPWO2020167668A5 JPWO2020167668A5 (https=) 2023-02-20
JP7612591B2 true JP7612591B2 (ja) 2025-01-14

Family

ID=69811875

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021547303A Active JP7612591B2 (ja) 2019-02-11 2020-02-10 抗ｃｌｅｃ２ｄ抗体及びその使用方法
JP2024229509A Pending JP2025062598A (ja) 2019-02-11 2024-12-25 抗ｃｌｅｃ２ｄ抗体及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024229509A Pending JP2025062598A (ja) 2019-02-11 2024-12-25 抗ｃｌｅｃ２ｄ抗体及びその使用方法

Country Status (10)

Country Link
US (2) US11827710B2 (https=)
EP (1) EP3924385A1 (https=)
JP (2) JP7612591B2 (https=)
KR (1) KR20220007584A (https=)
AU (1) AU2020222891A1 (https=)
CA (1) CA3129818A1 (https=)
IL (1) IL285401A (https=)
NZ (1) NZ778293A (https=)
SG (1) SG11202108403UA (https=)
WO (1) WO2020167668A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025062598A (ja) * 2019-02-11 2025-04-14 ズムトール バイオロジクス インコーポレイテッド 抗ｃｌｅｃ２ｄ抗体及びその使用方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115443140A (zh) * 2020-04-02 2022-12-06 苏州恒康生命科学有限公司 人ror-1抗体和抗ror-1-car-t细胞
EP4225795A4 (en) * 2020-10-05 2025-03-26 Monash University Clec9a antibodies
JPWO2022202985A1 (https=) * 2021-03-24 2022-09-29
WO2023039242A2 (en) * 2021-09-13 2023-03-16 Achelois Biopharma, Inc. Multivalent interferon particles compositions and methods of use
CN114685663B (zh) * 2022-04-07 2023-09-08 西南大学 一种抗胆固醇依赖性细胞溶素的抗体及其应用
CA3254800A1 (en) * 2022-05-31 2023-12-07 The Brigham And Women's Hospital, Inc. Anti-BMP9 antibodies and their methods of use
KR20250122456A (ko) * 2022-11-01 2025-08-13 프로비던스 헬스 앤드 서비시즈 - 오레곤 Fas 리간드에 특이적인 단일클론 항체 및 이의 용도
CN115894675B (zh) * 2023-02-03 2023-11-14 康复大学(筹) 新冠病毒SARS-CoV-2核衣壳蛋白单克隆抗体及其应用
WO2024226468A2 (en) * 2023-04-24 2024-10-31 Elpis Pharmaceuticals Armored anti-b7h3 car-t cells and uses thereof in cancer therapy
WO2025096542A2 (en) * 2023-10-30 2025-05-08 Immunitas Therapeutics, Inc. Clec2d binding proteins and related methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
WO1995022618A1 (en) 1994-02-22 1995-08-24 Dana-Farber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
US7147854B2 (en) 1997-06-23 2006-12-12 Yes Biotech Laboratories Ltd. Topical treatment of psoriasis using neutralizing antibodies to interleukin-8
US20040001804A1 (en) * 1999-12-30 2004-01-01 Mathew Porunelloor A. LLT uses thereof in immune system modulation
US9127052B2 (en) * 2010-06-29 2015-09-08 Centre National De La Recherche Scientifique LLT-1 antibodies with new functional properties
US9111624B2 (en) 2013-03-22 2015-08-18 Katsuyuki Fujita Semiconductor memory device
KR20220007584A (ko) * 2019-02-11 2022-01-18 주무토르 바이오로직스 인코포레이티드 항-clec2d 항체 및 이의 사용 방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Oncotarget，2016年09月08日，Vol.7/No.42，PP.68650-68661

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025062598A (ja) * 2019-02-11 2025-04-14 ズムトール バイオロジクス インコーポレイテッド 抗ｃｌｅｃ２ｄ抗体及びその使用方法

Also Published As

Publication number Publication date
US20240010733A1 (en) 2024-01-11
IL285401A (en) 2021-09-30
JP2022521705A (ja) 2022-04-12
EP3924385A1 (en) 2021-12-22
WO2020167668A1 (en) 2020-08-20
NZ778293A (en) 2026-02-27
US20200291120A1 (en) 2020-09-17
US11827710B2 (en) 2023-11-28
KR20220007584A (ko) 2022-01-18
AU2020222891A1 (en) 2021-08-05
SG11202108403UA (en) 2021-08-30
JP2025062598A (ja) 2025-04-14
US12460007B2 (en) 2025-11-04
CA3129818A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
JP7612591B2 (ja) 抗ｃｌｅｃ２ｄ抗体及びその使用方法
ES3003809T3 (en) Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides
JP7510879B2 (ja) 酸性ｐＨでＶＩＳＴＡに結合する抗体
AU2022259823A1 (en) Anti-CD73 antibodies and methods of use thereof
JP7716992B2 (ja) 骨髄細胞炎症性表現型を調節するための抗ｐｓｇｌ－１組成物及び方法、ならびにその使用
TW202019971A (zh) 抗間皮素抗體
WO2017159287A1 (ja) 癌の治療に用いるための細胞傷害誘導治療剤
TWI903448B (zh) 對抗檢查點分子之多特異性結合構築體及其用途
JP2021513368A (ja) 抗ｈｅｒ２抗体
WO2018088877A2 (ko) CD66c에 특이적으로 결합하는 항체 및 그의 용도
WO2022216887A1 (en) Novel anti-cd4 antibodies
JP2025526677A (ja) Ｂ７－ｈ３抗原結合性分子
KR20240058149A (ko) Vista 항원-결합 분자를 사용한 암의 치료 및 예방
WO2022187710A1 (en) Epha2 antibodies
KR102480815B1 (ko) 바이안테나리 루이스 b 및 루이스 y 항원에 결합하는 치료 항체
TW202342528A (zh) 抗人類ｃｘｃｌ１抗體
HK40102796A (zh) 用於癌症治疗的诱导细胞损伤的治疗药物
TW202600601A (zh) Ｔｒｏｐ２特異性抗原結合蛋白與細胞激素之共軛物
CA3218832A1 (en) Combined therapy using anti-cd300c antibody
TW202523694A (zh) 抗muc16抗體及其用途
HK40120830A (zh) 双特异性抗体融合分子及其使用方法
HK40118852A (zh) 对抗检查点分子的多特异性结合构建体及其用途
TW202604964A (zh) 對抗檢查點分子之多特異性結合構築體及其用途
HK1258783B (zh) 用於癌症治疗的诱导细胞损伤的治疗药物
BR122024002974A2 (pt) Agentes anticâncer que compreendem um anticorpo biespecífico, composição farmacêutica e seu uso

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241030

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241225

R150 Certificate of patent or registration of utility model

Ref document number: 7612591

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02